Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 69 clinical trials
Featured trial
A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of Subjects with Advanced Renal Cell Carcinoma

A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of

  • 222 views
  • 25 Mar, 2021
  • 1 location
Featured trial
  • 120 views
  • 25 Mar, 2021
  • 1 location
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

tested at different doses as single agent and in combination with Everolimus (RAD001, an mTOR inhibitor), and also in combination with Spartalizumab (PDR001, an anti-PD1) plus Taminadenant (NIR178, an

everolimus
vegf
mtor inhibitor
clear cell renal cell carcinoma
cancer
  • 16 views
  • 30 Jun, 2022
  • 10 locations
Itacitinib + Everolimus in Hodgkin Lymphoma

This is an open-label, single-group, Phase I/II study of itacitinib in combination with everolimus in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL).

gonadotropin
measurable disease
nivolumab
positron emission tomography/computed tomography
gilbert's syndrome
  • 1 views
  • 27 Jul, 2022
  • 1 location
Everolimus in Treating Patients With Recurrent or Progressive Low-Grade Glioma

RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is

  • 24 views
  • 07 Nov, 2020
  • 1 location
Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection (STARR)

Background Long-term success of organ transplantation is limited by the inexorable loss of graft function due to rejection. Prevalent dogma defends that allograft rejection is exclusively mediated by the adaptive immune system: T cells are responsible for cellular rejections and B cells producing Donor Specific Antibodies (DSA) are responsible for …

Accepts healthy volunteers
  • 0 views
  • 25 May, 2022
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

To evaluate the feasibility of administering HCQ, EVE or the combination in patients who have completed primary therapy for breast cancer and harbor bone marrow disseminated tumor cells.

primary tumor
tumor cells
triple-negative breast cancer
invasive breast cancer
cancer
  • 24 views
  • 14 Jun, 2022
  • 1 location
Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients

greater effect in everolimus vs. tacrolimus treated LTR, thus providing the rationale for a subsequent clinical trial to utilize EPO in combination with everolimus as a more successful pathway toward

  • 0 views
  • 02 May, 2022
  • 1 location
Optimal Treatment for Coronary Drug Eluting Stent In-stent Restenosis (OPEN-ISR)

are the: Magic Touch - sirolimus coated balloon Emperor - paclitaxel and dextran coated balloon Xience - chromium-cobalt everolimus eluting stent

  • 0 views
  • 08 Jul, 2022
  • 2 locations
SELUTION SLR™ 014 In-stent Restenosis

treatment with either the SELUTION SLR™ DEB or SOC to include contemporary DES (zotarolimus-eluting stents and everolimus-eluting stents only) or non-DEB BA. A maximum of 418 randomized subjects will be

ischemia
in stent restenosis
myocardial infarction
aspirin
everolimus
  • 0 views
  • 23 Apr, 2022
  • 1 location